WO2025106975A1 - Système d'administration de médicament en boucle fermée avec modulation de barrière hémato-encéphalique - Google Patents

Système d'administration de médicament en boucle fermée avec modulation de barrière hémato-encéphalique Download PDF

Info

Publication number
WO2025106975A1
WO2025106975A1 PCT/US2024/056393 US2024056393W WO2025106975A1 WO 2025106975 A1 WO2025106975 A1 WO 2025106975A1 US 2024056393 W US2024056393 W US 2024056393W WO 2025106975 A1 WO2025106975 A1 WO 2025106975A1
Authority
WO
WIPO (PCT)
Prior art keywords
drug delivery
permeability
brain barrier
stimulation
stimulation energy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/056393
Other languages
English (en)
Inventor
Francis A. Papay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cleveland Clinic Foundation
Original Assignee
Cleveland Clinic Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cleveland Clinic Foundation filed Critical Cleveland Clinic Foundation
Publication of WO2025106975A1 publication Critical patent/WO2025106975A1/fr
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
    • A61N1/3606—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
    • A61N1/36064—Epilepsy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
    • A61M5/14276—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body specially adapted for implantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N7/00—Ultrasound therapy
    • A61N2007/0004—Applications of ultrasound therapy
    • A61N2007/0021—Neural system treatment
    • A61N2007/0026—Stimulation of nerve tissue

Definitions

  • the present disclosure relates to a system and methods for timed modulation of the permeability of the blood brain barrier of a subject with the coordinated timing of the delivery of therapeutic agents to the central nervous system of the subject while the blood brain barrier is rendered more permeable.
  • this system can be used to render the blood brain barrier less permeable through timed modulation to control (or inhibit) the amount of noxious autogenous intravascular and other inflammatory factors allowed into the brain parenchyma.
  • the blood brain barrier is a selective, semipermeable membrane that lines the capillary blood vessels that supply the brain, and serves to inhibit the passage of potentially harmful molecules in the blood into the brain.
  • the BBB represents a significant obstacle to the delivery of therapeutic agents to the central nervous system. As the size of a therapeutic molecule increases, modulating the BBB to be permeable enough to allow its passage becomes more difficult.
  • chemotherapy and other immune modulating agents can contain very large antibodies that can be more effective when delivered directly to the central nervous system, which requires that the BBB be rendered more permeable.
  • Chemotherapy agents and other immunotherapies, particularly utilizing relatively large molecules are often administered several times over a short period (e.g., every few hours or days). Such frequent and periodic modulation of the blood brain barrier (BBB) for effective drug delivery can be cumbersome.
  • a drug delivery system includes an electronic stimulation implant, a drug delivery pump, and a computing device, which can include a timer, coupled to the electronic stimulation implant(s) and the drug delivery pump.
  • the electronic stimulation implant is configured to be implanted adjacent to one or more nerve(s) and/or ganglion nerve bundle(s) of a subject to deliver stimulation energy to the nerve to modulate a blood brain barrier of the subject to control (increase and/or decrease) permeability of the blood brain barrier.
  • the drug delivery pump is configurable to deliver (e.g. via intravascular, intrathecal, intraventricular, subdural, or directly) one or more therapeutic agent(s) to the subject through the blood brain barrier.
  • the computing device comprises a non-transitory, computer-readable medium storing instructions that, when executed by one or more processors of the computing device, cause the one or more processors to: activate the electronic stimulation implant to deliver the stimulation energy to the nerve(s) or nerve ganglion bundle(s) for a first time period; activate the drug delivery pump to deliver the therapeutic agent to the subject via the blood brain barrier over a second time period; deactivate the drug delivery pump to stop delivery of the therapeutic agent to the subject; and deactivate the electronic stimulation implant to stop delivering the stimulation energy to the nerve or change the electrical characteristics of the stimulation energy to cause reversal (closure, less permeability) of the blood brain barrier.
  • a drug delivery method includes the step of applying stimulation energy to a nerve, nerve ganglion bundle and/or blood vessel of a subject.
  • the stimulation energy may be electrical, ultrasonic, and/or electromagnetic energy.
  • low frequency energy may be applied to the nerve(s), and particularly to the craniofacial/skull based nerves, to stimulate the blood vessels of the blood brain barrier, thereby causing vasodilation to increase permeability of the blood brain barrier.
  • high-frequency ultrasonic energy may be applied directly to a brain parenchymal blood vessel(s) to cause vasodilation to increase permeability of the blood brain barrier.
  • the method further includes the steps of measuring a real-time parameter of the subject; determining that a blood brain barrier is permeable based on the real-time parameter meeting or exceeding a permeability threshold; operating a drug delivery pump to deliver a therapeutic agent; thereafter deactivating the drug delivery pump; and thereafter, stopping or changing the electrical characteristics of the application of the stimulation energy to lessen the permeability of the blood brain barrier.
  • the stimulation energy is adapted to increase or decrease permeability of the blood brain barrier of the subject.
  • FIGURE 1 shows a schematic diagram of embodiments of a system for drug delivery through the blood brain barrier as described herein.
  • FIGURE 2 shows a flow diagram of an example method for drug delivery through the blood brain barrier as described herein.
  • FIGURE 3 illustrates an exemplary time-plot of electrical stimulatory frequency delivered by an electronic stimulation implant over time to permeate the blood brain barrier.
  • FIGURE 4 illustrates a schematic block diagram of an example system for drug delivery that includes several stimulation devices to stimulate blood vessels, ganglion nerve bundles and/or nerves to modulate permeability the blood brain barrier.
  • FIGURE 5 illustrates an exemplary plot of the frequenc ies delivered by two electronic stimulation implants or devices over time that together modulate the permeation of the blood brain barrier by the stimulation of different neural targets (e.g., Vagus Nerve, Sphenopalatine Ganglion).
  • different neural targets e.g., Vagus Nerve, Sphenopalatine Ganglion.
  • the present disclosure relates to systems and methods to improve delivery of therapeutic agents past the blood brain barrier (BBB) and into the central nervous system of a patient.
  • BBB blood brain barrier
  • the system facilitates delivery of such agents across the BBB, but also is useful to control or minimize the passage of noxious inflammatory factors across the BBB in a permeable state and into the brain parenchyma to cause pathophysiologic changes.
  • Electronic stimulation e.g.
  • skull base ganglia and nerves such as the Sphenopalatine (Pterygopalatine) ganglion, the Trigeminal nerve, the Vagus nerve, and even more broadly, other nerve(s) in or communicating with the parasympathetic system of the cranial ganglia, can modulate the permeability of the BBB.
  • nerves such as the Sphenopalatine (Pterygopalatine) ganglion, the Trigeminal nerve, the Vagus nerve, and even more broadly, other nerve(s) in or communicating with the parasympathetic system of the cranial ganglia
  • the BBB may become more or less permeable depending on the frequency or other characteristics of the stimulation energy, in order to allow therapeutic agents to enter the central nervous system from the bloodstream that otherwise would have been blocked, and disallow intravascular autogenous inflammatory cellular noxious factors to pass into the brain’s neural tissues causing pathophysiologic changes.
  • focal ultrasound stimulation of intracranial blood vessels also can impact the permeability of the BBB focally associated with those vessels, thereby increasing permeability to facilitate passage of larger molecules such as antibodies, gene therapies, stem cells, and the like.
  • a combination of both ultrasound stimulation and electrical stimulation of parasympathetic nerves will augment the volume and permeability factors of the blood brain barrier.
  • Delivery of large molecular therapeutic agents to the central nervous system can be useful in treating various central nervous diseases such as, for example, brain tumors, Alzheimer’s disease, central nervous system lymphomas, leukemias and certain other cancers, central nervous system infections, and autoimmune and genetic central nervous system diseases.
  • normal or excessive permeability of the BBB can allow the passage of intravascular noxious autogenous inflammatory factors that can affect the inflammation and pathophysiology of the brain parenchyma in both acute and chronic diseases of the central nervous system. Controlling the BBB permeability to limit transmission of such factors can be useful when treating central nervous disease conditions.
  • An example would be to modulate, and thereby limit, the permeability of the BBB after a vascular stroke to inhibit passage of intravascular inflammatory factors that might otherwise pass (or be more likely to pass) and initiate peri-stroke infarct inflammation.
  • Such a methodology can limit the volume of the post- stroke infarct (neuron cell death).
  • the therapeutic molecular agents are so large that material increase in BBB permeability would be required to facilitate their passage.
  • several nerves and/or blood vessels can be stimulated through several different forms of stimulation energy (e.g. ultrasound and electrical) to provide a compounding modulation effect to materially increase the BBB permeability to allow such larger therapeutic molecules to pass through the BBB.
  • stimulation energy e.g. ultrasound and electrical
  • low frequency electrical energy applied to the nerve(s), and particularly the craniofacial/skull base nerves can increase BBB permeability.
  • high-frequency ultrasonic energy applied to blood vessels also can increase BBB permeability for the treated blood vessels.
  • At least two different energy types can be applied to the cranium (e.g., blood vessels and/or nerves) to provide a compounded stimulation effect to materially increase BBB permeability.
  • at least two different parts of the cranium e.g., two different blood vessels, two different nerves, a blood vessel and a nerve
  • the same or distinct modalities of stimulation at different locations can be applied simultaneously to yield a compounding effect to materially increase the permeability of the BBB, thereby rendering passage accessible to relatively large molecular species for specific treatments.
  • the stimulation of the nerve(s) and/or blood vessel(s) to increase permeability may be desirable to wait for a period of time before beginning delivery of the therapeutic agent to ensure the BBB has become sufficiently permeated. Accordingly, it may be desirable to ensure that the therapeutic agent is not administered until the BBB has been assessed to be sufficiently permeable. By waiting to deliver the therapeutic agent into the body until after the BBB is sufficiently permeable, unnecessary exposure and/or unwanted circulation of the therapeutic agent to other parts of the body outside of the BBB is reduced.
  • the stimulation of the nerve(s) and/or blood vessel(s) to increase BBB permeability may continue until the therapeutic agent delivery is complete. Once complete, the stimulation may be stopped such that the BBB returns to its baseline state.
  • different modalities of stimulation energy, and/or energies of different characteristics can be applied at suitable locations as described above to facilitate decreasing the permeability of the BBB.
  • relatively high-frequency electrical energy can be applied to the parasympathetic ganglion or nerve bundles to lessen permeability of the BBB, returning it to its baseline state.
  • one or more sensors may be arranged on or within the patient’s body to measure real-time parameters of the patient that indicate whether the BBB has been sufficiently permeated for the passage of a particular therapeutic agent.
  • the real-time parameters may include blood pressure, blood sugar, white blood cell count, red blood cell count, and/or levels of proteins, biomarkers, inflammatory markers, electrolytes, vitamins, and the like in the blood or cerebrospinal fluid (CSF), as well as other parameters that have been or can be measured periodically or in real time and correlated to BBB permeability.
  • CSF cerebrospinal fluid
  • elevated levels of albumin and/or immunoglobulins in the CSF can indicate BBB permeability; elevated levels of the S100B protein in the blood can indicate BBB permeability; and elevated levels of inflammatory markers (e.g., IL-6, TNF- ⁇ , IL- 1 ⁇ ) in the blood or CSF can indicate BBB permeability.
  • the one or more sensors may also be image devices configured to capture image data from the patient to determine BBB permeability.
  • dynamic contrast-enhanced MRI imaging can track the passage of a contrast agent, such as gadolinium across the BBB to determine where the BBB has become permeated.
  • Diffusion Tensor Imaging can detect microstructural changes in brain tissue that correlate with BBB permeability.
  • 18F- FDG PET scans can measure glucose uptake in the brain, which can correspond to BBB permeability since glucose transport is regulated by the BBB.
  • Cerebral blood flow can also be measured through MRT or PET scans, where changes in the blood flow can indicate BBB permeability changes, especially when combined with contrast agents that indicate BBB permeability.
  • MRI scans can also measure brain tissue water content, which if imbalanced can show BBB permeability.
  • Electrophysiological markers can also show BBB permeability, such as measurement of a patient’s transendothelial electrical resistance to measure the tightness of cell junctions, where lower values indicate an increase in BBB permeability; and measurement of a patient’s brain wave patterns (e.g., EEG changes). Changes in the osmotic balance across the BBB measured via osmotic agents (e.g., mannitol) can also indicate BBB permeability.
  • osmotic agents e.g., mannitol
  • the presence and concentration of the therapeutic agent in different parts of the body or body systems, as well as the residuary concentration in the blood stream following administration of a known dose, may also be correlated to provide an indication whether the BBB has been sufficiently permeated for the intended delivery of the therapeutic agent to the central nervous system.
  • certain real-time parameters will be more amenable to measurement in an ambulatory setting in order to supply feedback data for regulating the delivery of therapeutic agent. Whereas other such parameters will require a hospital or clinical setting.
  • the clinician can select a suitable real-time parameter to be measured and used to supply feedback data indicative of BBB permeability given the nature and setting of the particular therapy.
  • a closed-loop drag-delivery system configured to modulate the permeability of the BBB and to deliver therapeutic agents to the central nervous system via the BBB, wherein the delivery of the agent is timed or synchronized to correspond to one or more time periods when the BBB has been sufficiently permeated via modulation.
  • the system also can utilize feedback signals from one or more sensors that continuously or periodically detects one or more real-time parameters from the patient indicative of or correlated to BBB permeability in order to optimize therapeutic-agent delivery according to a timed or sequenced algorithm, e.g. corresponding to selected time periods.
  • Delivery of the therapeutic agent into a subject can be delayed until BBB permeability is determined; and preferably until said permeability has been determined to have reached a degree adequate to permit passage of the therapeutic agent into the central nervous system.
  • the system also can be used to delect, via the one or more sensors, real-time parameter(s) to provide an indication when the BBB permeability has been sufficiently reduced; or reduced back to a baseline state.
  • the disclosed system preferably is a closed-loop system that in desirable embodiments can be implemented using human-portable components, which allows a patient to receive therapeutic agents that need to permeate the BBB in an ambulatory setting outside of the hospital. This can materially reduce cost and increase patient quality of life, especially if the delivery of therapeutic agents is conducted on a frequent schedule.
  • the system 100 includes a drug delivery pump 102, a first electronic stimulation implant 110, and a processor 116 connected to the drug delivery pump 102 and the first electronic stimulation implant 110.
  • the first electronic stimulation implant 110 is operably coupled to a patient body 108 internally or externally.
  • the first electronic stimulation implant 110 can be implanted within the patient body 108 adjacent to a nerve and configured to deliver stimulation energy (such as electrical energy at different frequencies) to the nerve to modulate the BBB.
  • the first stimulation implant 110 can be implanted adjacent to or to target a particular intracranial brain blood vessel with suitable stimulation energy (e.g. ultrasonic energy) to modulate the blood brain barrier and increase its permeability.
  • suitable stimulation energy e.g. ultrasonic energy
  • the first electronic stimulation implant 110 is located entirely or partially external to the patient body 108, such as on the outside of the patient’s head wherein the stimulation implant 110 can act as a transducer effective to transmit RF energy to generate a perineural electrical field directed to the patient’s skull base ganglion or craniofacial nerves as desired.
  • the implant 110 can be powered through resonance induction (or other) stimulation energy through the skin to underlying skull base ganglion, craniofacial nerves, or to blood vessels as desired.
  • an externally disposed stimulation implant also can have leads that penetrate the skin and extend into the patient’s head, toward or adjacent to the nerve(s) and/or blood vessel(s) to be stimulated, increase or decrease the permeability of the BBB.
  • the drug delivery system 100 can further include a second electronic stimulation implant 112 operably coupled to the patient body 108 internally or externally, similar as the first stimulation implant 110 discussed above.
  • the first and second electronic stimulation implants 110, 112 may have different structures and/or may target different areas (e.g., nerves, blood vessels, etc.) of the patient body 108 to augment the modulation of the BBB.
  • a power supply 114 is coupled to the first and/or second electronic stimulation implants 110, 112.
  • the processor 116 can be coupled to, or part of a computing device that includes, a non-transitory, computer-readable medium that stores machine-readable instructions. When the instructions are executed, the processor 116 is configured to activate the first and/or second electronic stimulation implants 110, 112 to provide stimulation energy to nerves and/or blood vessels of the patient body 108. Stimulation of the nerves and/or blood vessels will modulate, e.g. increase, the permeability of the BBB such that it is rendered to a permeable state suitable to accommodate passage of desired therapeutic molecules.
  • the processor 116 can activate the drug delivery pump 102 pursuant to the machine-readable instructions, in order to deliver the therapeutic agent to the patient body 108 where it may permeate the BBB.
  • the processor 116 then deactivates the drug delivery pump 102 to stop the delivery of the therapeutic agent, and stops or adjusts the stimulation energy in order to reduce the permeability of the BBB (e.g. to return it to its baseline permeability state) once it no longer need be permeable to facilitate drug delivery.
  • Simply stopping delivery of stimulation energy in many cases should result in the BBB returning to its baseline permeability.
  • actively modulating the BBB to reduce its permeability with relatively high-frequency energy may prove an appropriate therapy to accelerate reducing BBB permeability to protect the central nervous system.
  • Lines of communication between the components of the system 100 are shown schematically as arrows in FIG. 1.
  • Such communication can be wireless, wired or a combination thereof.
  • the communication between the various components can be two-way, meaning that, for example, the drug delivery pump 102 sends data to the processors 116 and the processor 116 may send data to the drug delivery pump 102.
  • Such two-way communications can allow several components to send and receive feedback signals to ensure the system 100 is performing as intended; e.g. in accordance with a programmed or operative algorithm.
  • the illustrated system 100 further includes a sensor 118, which is also connected to the processor 116.
  • the sensor 118 is coupled to the patient body 108 internally or externally and is configured to detect a real-time parameter of the patient in real-time or periodically.
  • real-time parameters examples include blood pressure, blood sugar, white blood cell count, red blood cell count, other vital signs, as well as metabolic parameters such as serum-levels of certain proteins, electrolytes, vitamins, other matabolytes or blood components, and of the therapeutic agent, each as it may be correlated to or indicative of the permeability of the BBB.
  • the real-time parameter can be selected based on the extent to which it is either directly correlated to, or indicative of, the permeability of the BBB.
  • the processor 116 is configured to compare the detected parameter to a permeability threshold indicative of the BBB permeability for that detected parameter.
  • the processor 116 can be configured, e.g.
  • the processor 116 activates or increases the magnitude (or frequency, if applicable) of the stimulation energy in order to increase permeability.
  • the processor can reduce the delivery of stimulation energy (or adjust its characteristics, such as its frequency) via the stimulation implant(s) in order to reduce BBB permeability.
  • the processor 1 16 can modulate the application of the stimulation energy in response to successive or continuous measurements of the real-time parameter by the sensor 118 to ensure that permeability of the BBB continues to at least meet a threshold permeability before the drug delivery pump 102 delivers a full dose of the therapeutic agent and/or while the drug delivery pump 102 continues to deliver the full dose of the therapeutic agent to the patient body 108.
  • the drug delivery pump 102 may supply a test dose of the therapeutic agent to the patient.
  • the sensor 118 may then detect a real-time parameter that has been or can be correlated to whether the test dose of the therapeutic agent has entered the patient’s central nervous system.
  • a suitable sensor adapted to detect one of these real-time parameters could be used to provide an indication whether the BBB was penetrated by the test dose.
  • the processor 116 can deduce that the stimulation energy has yielded a sufficient increase in BBB permeability to deliver the therapeutic agent, and thus activate the drug delivery pump 102 to provide a full dose of the therapeutic agent to the patient body 108. Conversely, if the detected real-time parameter does not exhibit a change that would correlate to or imply delivery of the therapeutic agent across the BBB, then the processor 1 16 can deduce that the stimulation energy has not sufficiently modulated the BBB. The processor 116 may then operate the implant(s) 110, 112 to adjust the frequency and/or magnitude of stimulation energy.
  • the processor 116 may repeat the test dose delivery and collection of sensor data from the sensor 118 to once again determine whether the therapeutic agent has entered the patient’s central nervous system. This process can be repeated as part of an algorithm to modulate the BBB permeability prior to commencement of delivery of the full dose of therapeutic agent, as well as during delivery thereof to ensure sufficient or optimal BBB permeability.
  • the senor 118 can be coupled to another nerve interface to detect neuroactivity of a different nerve and provide an electrical signal corresponding to the neuroactivity.
  • the sensor 1 18 can be programmed to routinely collect and deliver data concerning the real-time parameter of the patient to the processor 116.
  • the sensor 118 can also be programmed to collect and deliver data concerning the real-time parameter upon an instruction requested by or given to the processor 116; e.g. via a user interface.
  • the real-time parameter measured by the sensor 118 can provide important feedback to the processor 116 such that the processor 116 can determine whether the drug delivery pump 102 and implants 110, 112 are functioning properly. This way, unnecessary permeation of the BBB is mitigated, which protects the patient’s central nervous system.
  • one or more sensors 118 may also be used to determine whether the BBB has returned back to its baseline impermeable state after a cycle of administering a dose of the therapeutic agent.
  • the processor 116 can deactivate the implant(s) 110, 112 such that the implant(s) 110, 112 no longer supply the stimulation energy to the patient body 108.
  • the processor 116 can adjust the stimulation energy provided by the implant(s) 110, 112 to actively induce permeability reduction of the BBB or return to its baseline state.
  • BBB permeability can be increased when cranial or facial nerves or nerve ganglia are stimulated with energy that activates the parasympathetic nervous system, thereby causing vasodilation within small-diameter cerebral vessels.
  • Such vasodilation may be induced by low-frequency energy stimulation, e.g. at frequencies less than 100 Hz.
  • a different stimulation energy may be applied to the same or different cranial or facial nerves to activate the sympathetic nervous system to promote vasoconstriction, thereby reducing BBB permeability to restrict the passage of harmful substances and inflammatory factors entering brain parenchyma.
  • Relatively high-frequency energy may be used to activate the sympathetic nervous system in this manner, e.g. frequencies of greater than 100 Hz.
  • the stimulation energy used to reduce BBB permeability may be a different frequency, come from a difference source, and/or be directed towards one or more different facial/cranial nerve(s) as described above, as well as different blood vessel(s), compared to the stimulation energy used to increase BBB permeability.
  • a combination of stimulation energies and/or nerves/blood vessels may be used to stimulate multiple nerve(s) and/or blood vessel(s) to modulate the BBB permeability, e.g. either increasing or decreasing, as desired according to a particular operative algorithm at appropriate time(s) and/or during appropriate time period(s).
  • the permeability BBB should reduce from its increased state, ideally returning to its baseline impermeable (or semi- permeable) state.
  • the sensor 118 may be activated to collect a real-time parameter for some predetermined time period after the deactivation of (or suitable change in) the stimulation energy designed to reduce BBB permeability, and the processor 116 may compare the realtime parameter data to an impermeability threshold to determine if and when the BBB successfully returns to its baseline impermeable state.
  • the impermeability threshold can be the same as or different than the permeability threshold.
  • the processor 116 may repeat the sensor data collection and comparison for another predetermined time period. After one or more findings of the BBB remaining permeable, the processor 116 may conduct some other protocol according to its instructions to ensure the BBB returns to its permeable state and/or to inform the patient or a clinician that the BBB is still permeable, in order that appropriate interventions might be considered.
  • Each of the drug delivery pump 102, the first electronic stimulation implant 110, the second electronic stimulation implant 112, the sensor 118, and the processor 116 can include any configuration of one or more electrical components to collect data, supply energy or therapeutic agents to the patient body 108, and/or communicate with at least one other component of the system 100.
  • the system may include other electronic components, such as a power supply (e.g., battery), a microprocessor (in addition to the one or more processor(s) already described), an electronic data storage unit (e.g., memory), a digital interface (e.g., an analog-to-digital converter (ADC) or digital-to-analog converter (DAC)), a signal processor (e.g., filter, amplifier), a recorder, a user interface (e.g., display, touchscreen, keyboard), electrodes (as the aforementioned sensor 118 and/or stimulation implants 110,112) to measure real-time parameters of the patient body 108 and/or to supply stimulation energy to the patient body 108, and/or a transponder for establishing wireless communication to or with a remote terminal such as a computer, tablet or smartphone.
  • a power supply e.g., battery
  • a microprocessor in addition to the one or more processor(s) already described
  • an electronic data storage unit e.g., memory
  • ADC analog
  • the communication between the various components of the system 100 may be automatic.
  • a user such as the patient, clinician, or caregiver, can monitor the communication between the various components of the system 100 and determine when to activate the implant(s) 110, 112 and drug delivery pump 102.
  • a patient device 124 such as a cell phone, laptop, or other device having a user interface, may be connected to the drug delivery pump 102, processor 116, implant(s) 110, 112, and/or sensor 118 such that the patient has the ability to send instructions to the components through the patient device 124.
  • a clinician may similarly use a clinician device 126 coupled to the system 100 to monitor the patient’s treatment and adjust the treatment (e.g., drug delivery timing, dosage) as needed.
  • the patient device 124 and/or clinician device 126 may have direct wireless communication with the components of the system 100 or may be indirectly connected to the components of the system 100 through the intemet/cloud 120 via WiFi or other network connection.
  • the processor 116 may be connected to the intemet/cloud 120, which facilitates communication with a server 122. This allows for the transfer of data between the server 122 and processor 116, the patient device 124, and/or the clinician device 126.
  • the system 100 may have its own user interface such that that displays data from the drug delivery pump 102, the implants 110, 112, and/or the sensor(s) 118, and which allows a user (e.g. the patient, a caregiver or a clinician) to supply instructions to the drug delivery pump 102, and/or to the implants 110, 112 for operation of the system 100.
  • the drug delivery pump 102 may be coupled to a therapeutic agent source (e.g., I.V. bag, syringe, cartridge) and be configured to deliver 104 a particular dosage of the therapeutic agent over a particular period of time to the patient body 108.
  • the drug delivery pump 102 comprises an infusion lube 106.
  • the infusion tube 106 or other component of the drug delivery pump 102 can be coupled to the patient body 108 in various ways to deliver the therapeutic agent intravenously, intrathecally, intra-arterially, intraventricularly, or combinations thereof.
  • the therapeutic agent source and/or the infusion tube 106 are semi-permanently attached to the drug delivery pump 102 and the patient body 108 such that they remain connected to the patient body 108 even when the drug delivery pump 102 and implant(s) 110, 112 are deactivated.
  • the therapeutic agent source and/or the infusion tube 106 may be connected to the drug delivery pump 102 and/or the patient body 108 upon a notification from the processor 116 that it is time for another dosage of the therapeutic agent.
  • the therapeutic agent Prior to the notification, the therapeutic agent is not delivered to the patient body 108. This can increase treatment efficacy by minimizing unwanted circulation of the therapeutic agent outside of the BBB, and instead ensuring delivery where it will provide the desired therapy, in central nervous system. The patient or caregiver may then disconnect the therapeutic agent source and/or the infusion tube 106 upon completion of the dosage delivery.
  • the processor 116 may be housed within the drug delivery pump 102, within a different component of the system 100, or it may contain its own separate housing.
  • the processor 116 may communicate with the power supply 114 of the implant(s) 110, 112 to activate the delivery of stimulation energy by the implant(s) 110, 112.
  • the implant(s) 110, 112 can be powered by RF energy to generate a perineural electrical field that stimulates or over stimulates the nerve or nerve ganglia.
  • the implant(s) 110, 112 and/or sensor 118 are powered through electromagnetic resonance induction, where the implant(s) 110, 112 and/or sensor 118 are within the patient body 108 but are powered by a power supply 114 located outside of the patient body 108.
  • the patient places a power supply 114 close to the implant(s) 110, 112 and/or sensor 118 when notified by the processor 116 to provide power to the implant(s) 110, 112 and/or sensor 118 within the patient body 108 through electromagnetic induction.
  • the patient may hold the power supply 114 near the implant(s) 110, 112 and/or sensor 118 until the drug delivery cycle is complete.
  • the power supply 114 may directly power the stimulation energy provided by the implant(s) 110, 112.
  • the power supply 114 for the implant(s) 110, 112 and/or sensor 118 can include rechargeable batteries and be despised inside the patient’s body 108.
  • the patient may rest his/her head (if that is where the power supply 114 is located, for example) on a power pad for a charging time period to recharge the power supply 114.
  • the implant(s) 110, 112 and sensor 118 may share one or more power supplies 114 or each may have its own, local power supply 114. After charging the associated power supply(ies) 114, the implant(s) 110, 112 can provide the stimulation energy to the patient body 108 using the stored energy in the power supply 114.
  • the implant(s) 110, 112 and/or sensor 118 may utilize a power supply that relies on batteries that are not rechargeable, in which case the batteries must be replaced once exhausted. Such non- rechargeable power supplies ideally will not be implanted within the patient body.
  • FIG. 2 shows a flow diagram for an example method 200 of using the disclosed drug delivery system 100.
  • a signal is received indicating that it is time to administer a dose of a therapeutic agent to a patient.
  • the signal is based on a predetermined dosage schedule within the instructions of the processor 116, a command input by a user (e.g., patient, caregiver, clinician) at a user interface (e.g., patient device 124, clinician device 126), and/or data from the sensor 118 indicative of the patient body 108 being ready for the dosage.
  • the processor 116 may provide a signal to the drug delivery pump 102 and/or and implants 110, 112 to start the dosage cycle by proceeding to step 204.
  • stimulation energy is applied to, e.g. a facial nerve of the patient to facilitate increased permeability of the BBB of the patient.
  • the stimulation energy is applied by the one or more of the implants 1 10, 112 or other stimulation devices.
  • the stimulation energy is applied over a first time period, where the start of the first time period begins at step 204.
  • the processor 116 collects sensor data from the sensor 118 related to a real-time parameter of the patient body 108.
  • the stimulation energy may continue to be provided during step 206 to continue to stimulate the nerve (for example) to modulate the BBB permeability.
  • the processor 116 may compare the real-time parameter to a threshold that is indicative of or correlated to the BBB being in a sufficiently permeable state for the desired treatment.
  • the threshold can be dependent on the patient (e.g., weight, height, age) as well as the type and size of the therapeutic agent to be delivered to the patient body 108.
  • step 208 After the comparison in step 208, the next step of the method 200 depends on the comparison result from step 208.
  • step 210 if the comparison indicates that the BBB is suitably permeable, then the method 200 proceeds to step 212.
  • the drug delivery pump is activated to deliver the therapeutic agent to the central nervous system through the permeable BBB of the patient.
  • step 218 if the comparison indicates that the BBB is not permeable, then the method 200 proceeds to step 220.
  • the processor 116 adjusts one or more parameters of the stimulation energy.
  • the processor 116 may adjust the stimulation energy by changing the output, such as the frequency, of the stimulation energy delivered by one or more of the implant(s) 110, 112 and/or may activate another implant or stimulation device to stimulate other nerves and/or blood vessels effective to modulate the permeability of the BBB.
  • the method may again repeat steps 206 and 208 to collect new sensor data to determine if the adjustments at step 220 achieved a desirable state of permeability for the BBB.
  • Steps 206, 208, 218, and 220 may continuously repeat until at step 210 the comparison indicates that the BBB has reached a suitably permeable state for the method proceeds to step 212.
  • the drug delivery pump 102 is activated for a second time period that begins at the start of step 212. The duration of the second time period can be based on the therapeutic agent to be delivered and the anticipated time needed to deliver the full dose. While the drug delivery pump 102 is activated in step 212, the delivery of stimulation energy commenced at step 204 continues in order to maintain suitable BBB modulation to ensure that it remains permeable to the therapeutic agent during delivery. As also seen in Fig.
  • steps 206, 208, 210, 218 and 220 can be executed cyclically while the delivery pump is operating to deliver the therapeutic agent, based on real-time or periodic feedback from the real-time parameter(s) in order to modulate the BBB to ensure it remains suitable permeable during drug delivery.
  • the second time period for drug delivery overlaps with the first time period for delivery of stimulation energy to ensure the BBB remains in a suitably permeable state during drug delivery.
  • the collection of sensor data in step 206 as well as steps 208 and 210 may characterized as occurring during a third time period, not necessarily the same as either the first or second time periods, but optionally overlapping with one or both of them as desired in order to supply feedback data concerning real-time parameters during delivery of stimulation energy and therapeutic-agent delivery.
  • the start of the second time period relating to step 212 starts preferably after the start of the first time period relating to step 204 and preferably after the start of the third time period relating to step 206.
  • the start of the third time period may be delayed from the start of the first time period by some predetermined interval to give the BBB time to become more permeable before starting collection of sensor data indicative of the BBB permeability.
  • the drug delivery pump 102 sends a feedback signal to the processor 116 indicating the dose of the therapeutic agent has been delivered to the central nervous system.
  • the second time period relating to drug delivery ends.
  • step 216 the processor 116 instructs the implant(s) 110, 112 and/or other stimulation devices to adjust or cease the stimulation energy to decrease permeability of the BBB.
  • step 216 includes the implant(s) 110, 112 and/or other stimulation devices applying a different stimulation energy to one or more nerve(s) or blood vessel(s) to reduce the permeability of the BBB.
  • the first time period relating to stimulation energy application to increase BBB permeability ends. The first time period may start before and end after the second time period to ensure the BBB is in a suitably permeable state during drug delivery over the second time period.
  • the method 200 may then proceed from step 216 back to step 202 when it is time for another dose administration of the therapeutic agent.
  • the one or more processor(s) 116, the drug delivery pump 102 and the stimulation implant(s) 110, 112 are coupled together to provide a closed-loop drug delivery system 100, wherein the pump delivers a therapeutic agent to the body based on instructions from the processor(s), during time period(s) when the implant(s) is/are similarly controlled by the processor(s) to ensure a suitably permeable BBB.
  • data from one or more sensor(s) also supplied to the processor(s) can provide an indication both when and the degree to which it is desirable to adjust the delivery of stimulation energy to modulate BBB permeability, as well as to adjust the delivery of the therapeutic agent via the pump to ensure it is being delivered only when the BBB is suitably permeable to accommodate passage of the therapeutic agent.
  • the system is a closed loop insofar as the processor is operative to modulate BBB permeability, and operate the pump to deliver therapeutic agent during suitable times in a closed control loop.
  • Data from the aforementioned sensor(s) further can be used to moderate that closed loop to ensure optimal stimulation of nerves/blood vessels and drug-delivery rates during a course of drug delivery.
  • the method 200 omits steps 206, 208, 210, 218, and 220 such that step 204 proceeds directly to step 212.
  • the start of the second time period relating to step 212 may be delayed from the start of the first time period relating to step 204 by some predetermined time that is or has been correlated to a presumptive state of the BBB that is sufficiently permeable to accommodate drug delivery.
  • the system still is a closed-loop system insofar as control of the pump to facilitate drug delivery remains controlled by the processor(s) based on (and ideally confined to a time period when) the BBB being (has been) rendered sufficiently permeable via stimulation energy, also controlled by the processor(s).
  • this closed-loop architecture will not benefit from the feedback control afforded by steps 206, 208, 210, 218 and 220. It should be noted that in these and other embodiments, it is possible for the first and second time periods to start at the same time; although this may not be desired. [0048] It will be appreciated that the method of FIG. 2 is exemplary and that additional steps, such as the use of additional stimulation devices or implants, additional sensor measurements, and the like, are also within the scope of this disclosure. Other steps not mentioned above also may be omitted.
  • FIG. 3 illustrates an example frequency versus time plot to illustrate modulation of stimulation energy that can be provided by the first electronic stimulation implant 110.
  • the time between t0 to t1 represents a time period in the drug delivery method before the first electronic stimulation implant 110 is activated to deliver a stimulation energy.
  • a first frequency fl is supplied to the first electronic stimulation implant 110.
  • the first frequency f1 is often zero to save power supply but in some embodiments can be greater than zero such that the first electronic stimulation implant 110 supplies at least some kind of frequency (e.g., f1) at all times.
  • the first electronic stimulation implant 110 is activated to deliver a second frequency f2.
  • the second frequency f2 corresponds to the stimulation energy intended to cause the BBB to change from a baseline impermeable state into a desirably permeable state.
  • the second frequency f2 may be applied continuously or as a series of pulses.
  • the sensor 118 may measure a real-time parameter.
  • the processor 116 may compare the real-time parameter to a permeability threshold.
  • the processor 116 may determine that the real-time parameter has not met the permeability threshold, and that the frequency of the first electronic stimulation implant 110 needs to be adjusted. For example, at t4, the frequency of the first electronic stimulation implant 110 is changed from f2 to f3. While in FIG.
  • the sensor 118 may again measure a real-time parameter.
  • the processor 116 may compare the real-time parameter to the permeability threshold and determine that the threshold has been met or exceed.
  • the drug delivery pump 102 may begin supplying the therapeutic agent to the patient body 108 through the permeable BBB.
  • the drug delivery pump 102 may stop supplying the therapeutic agent at time t7.
  • the first electronic stimulation implant 110 may stop supplying (or adjust the characteristics of) the stimulation energy applied to return the BBB permeability to its baseline state (e.g., f1) since drug delivery has concluded.
  • the time period beginning at tl and ending at t8 may correspond to the first time during which the first electronic stimulation implant 110 supplies the stimulation energy f2 and f3 (the latter representing an adjustment based on sensor data suggesting that the BBB had not yet been sufficiently permeable at f2).
  • the time period beginning at t6 and ending at t7 may correspond to the second time period during which the drug delivery pump 102 supplies the therapeutic agent to the patient body 108.
  • the time period beginning t2 and ending at t6 may correspond to the third time period during which the system 100 uses the real-time parameter from the sensor 118 (measured continuously or periodically) to determine whether the BBB is sufficiently permeable.
  • the drug delivery system 100 can include several stimulation devices to provide different types or magnitudes of stimulation energy to various parts of the patient body 108.
  • the system 100 can include a first electronic stimulation implant 110 and a second electronic stimulation implant 112.
  • the system 100 can further include a third stimulation device 402 and/or a fourth stimulation device 404.
  • the third and fourth stimulation devices 402, 404 are coupled to and controlled by the processor 116.
  • the third and/or fourth stimulation devices 402, 404 may provide high-frequency ultrasonic energy and/or electromagnetic frequency energy to a blood vessel and/or nerve in the cranium to permeate the BBB.
  • the third and/or fourth stimulation devices 402, 404 may be located internally, externally, or a combination thereof to the patient body 108.
  • Each of the third and/or fourth stimulation devices 402, 404 can be powered using various techniques such as those described above (e.g., batteries, rechargeable batteries, electromagnetic induction, etc.) with respect to the implants 110, 112.
  • the first and/or second electronic stimulation implants 110, 112 are omitted from the drug delivery system 100 and one of the third and/or fourth stimulation devices 402, 404 are used for BBB modulation.
  • various implants/devices 110, 112, 402, 404 can provide a compounding modulation effect on the BBB permeability to allow larger therapeutic agents into the central nervous system past the BBB.
  • energy e.g., low frequency energy, high- frequency ultrasonic energy, and/or electromagnetic frequency energy
  • the stimulation parameters may vary depending on the location of the desired nerve and/or blood vessel to be activated.
  • stimulation energy provided to a nerve is often hemispherical such that only one side of the BBB can be made sufficiently permeable to facilitate drug delivery; stimulation energy that is electromagnetic provided to a blood vessel is regional; and stimulation energy that is high-frequency ultrasound provided to a blood vessel is focal.
  • parasympathetic neuromodulation that opens up the BBB hemispherically can be combined with ultrasonic and/or electromagnetic energy to augment the focal effect of the BBB permeability.
  • a drug delivery system 100 may be designed to include one or more devices (e.g., 110, 112, 402, 404) coupled to a processor 116 to create permeation in a desired area of the BBB based on the type of therapeutic agent to be delivered.
  • a drug delivery system 100 comprises more than one stimulation device, such as those shown in FIG. 4, each device's timing and energy type/amount can be modulated dining the drug delivery method. Even if a drug delivery system 100 comprises multiple stimulation energy devices, only one or two may be activated during the drug delivery method, depending on how easily the BBB can be modulated for permeability.
  • FIG. 5 another example of a frequency versus time plot is illustrated.
  • the time and frequencies illustrated may indicate the same or similar steps as described with respect to FIG. 3.
  • a first stimulation device may be activated to provide a second frequency f2 to particular nerve and/or blood vessel of the patient at lime 11, as shown by line 502.
  • the processor 116 may activate a second stimulation device at time t4 to provide a third frequency f3 to a particular nerve and/or blood vessel of the patient, as shown by line 504.
  • the sensor data at t5 and t6 may be indicative of the BBB being sufficiently permeated.
  • Both stimulation devices may remain activated until time t8 at which the drug delivery method has concluded for a particular dose of therapeutic agent.
  • the second stimulation device may be activated during a fourth time period between time t4 and t8.
  • the start of the fourth time period may follow the start of the first time period or may be simultaneous with the start of the first time period.
  • the start of the delivery of the therapeutic agent may occur after the start of the first and fourth time periods.
  • the first and/or second stimulation devices may each stop providing stimulation energy and/or adjust the stimulation energy to reduce BBB permeability at time t8.
  • the magnitude and frequencies of stimulation energy supplied by each stimulation device at time 18 may be the same or different.

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention propose un système d'administration de médicament et comprend un implant de stimulation électronique, une pompe d'administration de médicament et un dispositif informatique couplé à l'implant de stimulation électronique et à la pompe d'administration de médicament. L'implant de stimulation électronique est conçu pour être implanté de manière adjacente à un nerf et/ou un vaisseau sanguin d'un sujet. Le dispositif informatique stocke des instructions qui, lorsqu'elles sont exécutées, amènent un ou plusieurs processeurs à activer l'implant de stimulation électronique pour administrer de l'énergie de stimulation au nerf/vaisseau sanguin pour moduler une barrière hémato-encéphalique du sujet pour augmenter sa perméabilité. Le processeur active, lorsque cela lui est ordonné, la pompe d'administration de médicament pour administrer un agent thérapeutique au sujet par l'intermédiaire de la barrière hémato-encéphalique une fois sa perméabilité ajustée de manière appropriée. Le processeur peut en outre ordonner à l'implant de stimulation électronique d'ajuster ou de cesser la première administration d'énergie de stimulation une fois que l'administration de médicament est achevée pour réduire la perméabilité de la barrière hémato-encéphalique.
PCT/US2024/056393 2023-11-17 2024-11-18 Système d'administration de médicament en boucle fermée avec modulation de barrière hémato-encéphalique Pending WO2025106975A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363600257P 2023-11-17 2023-11-17
US63/600,257 2023-11-17

Publications (1)

Publication Number Publication Date
WO2025106975A1 true WO2025106975A1 (fr) 2025-05-22

Family

ID=93796550

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/056393 Pending WO2025106975A1 (fr) 2023-11-17 2024-11-18 Système d'administration de médicament en boucle fermée avec modulation de barrière hémato-encéphalique

Country Status (1)

Country Link
WO (1) WO2025106975A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12383735B2 (en) 2023-04-28 2025-08-12 P Tech, Llc System and method for affecting porosity of tissue barriers, including blood brain barrier

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004010923A2 (fr) * 2002-07-31 2004-02-05 Brainsgate Ltd. Apport de composes a l'encephale par modification de proprietes de la barriere hemato-encephalique et de la circulation cerebrale
US7657316B2 (en) * 2005-02-25 2010-02-02 Boston Scientific Neuromodulation Corporation Methods and systems for stimulating a motor cortex of the brain to treat a medical condition
US20120253261A1 (en) * 2011-03-29 2012-10-04 Medtronic, Inc. Systems and methods for optogenetic modulation of cells within a patient
CN113368386A (zh) * 2021-06-21 2021-09-10 温州医科大学慈溪生物医药研究院 一种结合电刺激和超声的大分子药物入脑递送系统

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004010923A2 (fr) * 2002-07-31 2004-02-05 Brainsgate Ltd. Apport de composes a l'encephale par modification de proprietes de la barriere hemato-encephalique et de la circulation cerebrale
US7657316B2 (en) * 2005-02-25 2010-02-02 Boston Scientific Neuromodulation Corporation Methods and systems for stimulating a motor cortex of the brain to treat a medical condition
US20120253261A1 (en) * 2011-03-29 2012-10-04 Medtronic, Inc. Systems and methods for optogenetic modulation of cells within a patient
CN113368386A (zh) * 2021-06-21 2021-09-10 温州医科大学慈溪生物医药研究院 一种结合电刺激和超声的大分子药物入脑递送系统

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12383735B2 (en) 2023-04-28 2025-08-12 P Tech, Llc System and method for affecting porosity of tissue barriers, including blood brain barrier
US12544569B2 (en) 2023-04-28 2026-02-10 Realeve, Llc System and method for affecting porosity of tissue barriers, including blood brain barrier

Similar Documents

Publication Publication Date Title
US6845267B2 (en) Systems and methods for modulation of circulatory perfusion by electrical and/or drug stimulation
US11376438B2 (en) Managing therapy delivery based on physiological markers
US9421371B2 (en) Implantable system enabling responsive therapy for pain
US10046164B2 (en) Implantable neurostimulator supporting trial and chronic modes
US8412334B2 (en) Treatment of mood and/or anxiety disorders by electrical brain stimulation and/or drug infusion
US6782292B2 (en) System and method for treatment of mood and/or anxiety disorders by electrical brain stimulation and/or drug infusion
EP2121123B1 (fr) Modulation de la fonction renale par stimulation d'energie electrique
US8768452B2 (en) Implantable neurostimulator supporting trial and chronic modes
US7155279B2 (en) Treatment of movement disorders with drug therapy
US20050075701A1 (en) Device and method for attenuating an immune response
US20060100667A1 (en) Methods and systems of achieving hemodynamic control through neuromodulation
US20050075702A1 (en) Device and method for inhibiting release of pro-inflammatory mediator
US20050033376A1 (en) Systems and methods for trestment of obesity and eating disorders by electrical brain stimulation and/ or drug infusion
US20110264034A1 (en) Medical therapy modification authorization techniques
WO2015153675A1 (fr) Méthode et système de stimulation thérapeutique du cerveau à l'aide d'impulsions électromagnétiques
WO2025106975A1 (fr) Système d'administration de médicament en boucle fermée avec modulation de barrière hémato-encéphalique
US9566450B2 (en) Medical device communication with wireless telemetry head
US20250367442A1 (en) System and Method for Affecting Porosity of Tissue Barriers, Including Blood Brain Barrier
JP2018518307A (ja) 効果器を調節するための方法および装置
US20230355975A1 (en) Neuromodulation techniques to create a nerve blockage with a combination stimulation/block therapy for glycemic control
US20240198107A1 (en) Splanchnic neuromodulation for heart conditions
US20250281753A1 (en) Closed-loop feedback and treatment
JP2022506139A (ja) 血圧制御装置、血圧制御装置の制御プログラムを記憶する非一時的なコンピュータ可読記憶媒体および血圧制御方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24817817

Country of ref document: EP

Kind code of ref document: A1